AVPR2 and autosomal dominant polycystic kidney disease: This fact has been further studied, reviewed, and understood in ADPKD, at preclinical [147,148] and clinical levels [149], to the point that Tolvaptan (an vasopressin V2 receptor inhibitor) was approved for use in human patients [150] and an ongoing trial for children with ADPKD (Tolvaptan (NCT02964273)) [151].